Trial Profile
The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 from The Latent Reservoir (CLEAR) Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CLEAR
- 02 Sep 2021 Results (n=13) of a retrospective study assessing candidate host epigenetic biomarkers predicting LRA efficacy and HIV-1 rebound kinetics in people with HIV on virologically suppressive antiretroviral therapy participated in this trial published in the AIDS
- 24 Feb 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 06 Aug 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.